In vitro evaluation of pan-PI3-kinase inhibitor SF1126 in trastuzumab-sensitive and trastuzumab-resistant HER2-over-expressing breast cancer cells. - Wikidata - awgldk - TriplyDB

In vitro evaluation of pan-PI3-kinase inhibitor SF1126 in trastuzumab-sensitive and trastuzumab-resistant HER2-over-expressing breast cancer cells.

In vitro evaluation of pan-PI3-kinase inhibitor SF1126 in trastuzumab-sensitive and trastuzumab-resistant HER2-over-expressing breast cancer cells.

http://www.wikidata.org/entity/Q33599144

about

Ramentaceone, a Naphthoquinone Derived from Drosera sp., Induces Apoptosis by Suppressing PI3K/Akt Signaling in Breast Cancer Cells Personalizing HER2-targeted therapy in metastatic breast cancer beyond HER2 status: what we have learned from clinical specimens Human epidermal growth factor receptor-2-positive breast cancer: Current management of early, advanced, and recurrent disease.The PI-3 kinase-Akt-MDM2-survivin signaling axis in high-risk neuroblastoma: a target for PI-3 kinase inhibitor intervention.Growth differentiation factor 15 (GDF15)-mediated HER2 phosphorylation reduces trastuzumab sensitivity of HER2-overexpressing breast cancer cells.Targeting Bcl-2 in Herceptin-Resistant Breast Cancer Cell Lines.Pharmacologic inhibition of mTOR improves lapatinib sensitivity in HER2-overexpressing breast cancer cells with primary trastuzumab resistance.Pharmacological strategies to overcome HER2 cross-talk and Trastuzumab resistance.Deciphering the role of insulin-like growth factor-I receptor in trastuzumab resistance.New developments in the treatment of HER2-positive breast cancer Targeting the PI3K/Akt/mTOR pathway for breast cancer therapy Mechanisms of Adipocytokine-Mediated Trastuzumab Resistance in HER2-Positive Breast Cancer Cell Lines.Role of trastuzumab in the management of HER2-positive metastatic breast cancer.PI3K and Akt as molecular targets for cancer therapy: current clinical outcomes.Development of phosphoinositide-3 kinase pathway inhibitors for advanced cancer Potential role of PI3K inhibitors in the treatment of breast cancer.Targeting the mTOR pathway in breast cancer.Synthesis and anticancer activity of the (R,S)-benzofused 1,5-oxathiepine moiety tethered to purines through alkylidenoxy linkers.Effect of microencapsulation shear stress on the structural integrity and biological activity of a model monoclonal antibody, trastuzumab.Fatty acid synthase regulates proliferation and migration of colorectal cancer cells via HER2-PI3K/Akt signaling pathway.

P2860

Q28553060-1A9C1A53-D115-4217-93B4-10962E543C1A Q33735413-EB400B66-0DA2-4EF7-9B4D-A3DAF4046886 Q35018233-DBECAE68-1096-4295-A9B7-01DAE80C458F Q35127189-25CCFA58-221E-452A-9653-944BC78BE52A Q35316842-4F437425-E850-4D31-97CF-BCF62951049D Q35599629-367419D4-5114-4FBC-871A-C336BC3B1136 Q35783451-2699CA6A-1705-4219-9F39-0DB8CCC3F5B3 Q35803226-A4A8F434-ED71-4C90-AE81-9F3608D8D197 Q36102124-D7C3929E-718D-4EF2-B9FD-741DDF7CF5E4 Q37016382-03312750-255E-4C74-A191-182A8B2BF766 Q37047669-72ACD1BB-F7D3-42D8-84D1-7894CA8A53E5 Q37263096-15F7765B-6F14-4849-A7AE-A530562A0FFF Q37355370-3D1059E6-C44A-439A-B112-91ED12D5F2B6 Q37727180-58096EC8-744D-4E61-ABCD-33F8E3C22E65 Q37738756-F8703A87-82D6-4089-A51D-5C3E2DAF4808 Q37783617-574DC87B-8BDA-4CA0-B822-F0FDC09AC7B3 Q39390640-6013B5B7-E559-4522-8529-B726D61C9496 Q39499289-FA7B91E1-FE5B-4F95-827E-AF22F5E5A1BF Q42830746-D42EEDAD-FCA6-4A48-996A-814812839F92 Q54492986-AC1E33C8-0167-4534-8958-5260A5317CE6

P2860

In vitro evaluation of pan-PI3-kinase inhibitor SF1126 in trastuzumab-sensitive and trastuzumab-resistant HER2-over-expressing breast cancer cells.

http://www.wikidata.org/entity/Q33599144

description

2009 nî lūn-bûn

@nan

2009 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

In vitro evaluation of pan-PI3 ...... xpressing breast cancer cells.

@ast

In vitro evaluation of pan-PI3 ...... xpressing breast cancer cells.

@en

type

label

In vitro evaluation of pan-PI3 ...... xpressing breast cancer cells.

@ast

In vitro evaluation of pan-PI3 ...... xpressing breast cancer cells.

@en

prefLabel

In vitro evaluation of pan-PI3 ...... xpressing breast cancer cells.

@ast

In vitro evaluation of pan-PI3 ...... xpressing breast cancer cells.

@en

P1433

Q33599144-3C5D1037-9D1C-4707-9ECC-B6B7F6DD33EC

P1476

Q33599144-BE935757-37C3-4521-85B4-CB392A79C0EB

P2093

Q33599144-1DB54478-C0A7-42B4-B96D-C1629370FE21

Q33599144-89FD3199-08A8-418B-98E6-02AA7F3B93D2

Q33599144-9E43E591-0A16-4F4C-A36C-09B78853B9C9

Q33599144-B5925289-4908-4A31-A83B-29C7FDA08FDF

Q33599144-D6EC227F-5B73-4DF4-9617-6E7A60D17342

P2860

Q33599144-044B84D7-9C44-4EBE-B007-4779DDC0FAE2

Q33599144-052319A4-18B8-4C5F-A956-8650F303EEC0

Q33599144-116D16CA-28DB-4C66-90CB-EAB8C6108B00

Q33599144-2954B091-68CA-488A-A2BC-60218035F2BF

Q33599144-3333F4FE-D6FB-4690-A722-C981E081F3E5

Q33599144-459DD27D-D198-488E-AFE2-F8E1D43541F7

Q33599144-515FB823-C570-4D62-982D-BE9DF30C24ED

Q33599144-78D6057A-B4E1-4FA3-B147-D6E1F511B3A9

Q33599144-824E5B96-7EAF-457B-9BE0-76C3B12264C3

Q33599144-88917F16-B687-4361-8E4B-ACDA5624DC5F

P2888

Q33599144-7E6A3390-E925-4548-8613-E1F8042EB9CB

P304

Q33599144-712A896E-A65D-45CB-B34D-F40E1F8F1195

P31

Q33599144-43BF5614-0776-4558-A1A5-A15E564B2275

P356

Q33599144-6951B37D-7ABE-4CE0-BDFD-C18E2AABEDD5

P433

Q33599144-45E056F5-A3DB-4056-9CCD-A5A2D6737F6E

P478

Q33599144-36F20E9B-639B-4810-999B-2C0C4B59B09F

P577

Q33599144-AD4E268D-453A-41EA-A867-D52C5FA24C0D

P5875

Q33599144-7002A91E-D2FB-487E-8056-86B80C6B44A0

P6179

Q33599144-34F39CC4-6464-48BB-91E9-240B03BB2BE9

P698

Q33599144-F74A425D-3EF0-48E7-AA01-016621503E8B

P932

Q33599144-34048670-653C-45AA-906C-0FEB586B66A3

P356

S00280-009-1075-9

P1433

Cancer Chemotherapy and Pharmacology

P1476

In vitro evaluation of pan-PI3 ...... xpressing breast cancer cells.

@en

P2093

Donald L Durden

http://www.w3.org/2001/XMLSchema#string

Rita Nahta

http://www.w3.org/2001/XMLSchema#string

Ruth M O'Regan

http://www.w3.org/2001/XMLSchema#string

Tongrui Liu

http://www.w3.org/2001/XMLSchema#string

Tuba Ozbay

http://www.w3.org/2001/XMLSchema#string

P2860

Humanization of an anti-p185HER2 antibody for human cancer therapy

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer.

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

Akt/protein kinase B signaling inhibitor-2, a selective small molecule inhibitor of Akt signaling with antitumor activity in cancer cells overexpressing Akt.

Nordihydroguaiaretic acid, a cytotoxic insulin-like growth factor-I receptor/HER2 inhibitor in trastuzumab-resistant breast cancer

Mechanisms of disease: the PI3K-Akt-PTEN signaling node--an intercept point for the control of angiogenesis in brain tumors.

Monoclonal antibody 14C5 targets integrin alphavbeta5.

P2888

s00280-009-1075-9

P304

697-706

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00280-009-1075-9

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

65

http://www.w3.org/2001/XMLSchema#string

P577

2009-07-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26699563

http://www.w3.org/2001/XMLSchema#string

P6179

1035778053

http://www.w3.org/2001/XMLSchema#string

P698

19636556

http://www.w3.org/2001/XMLSchema#string

P932

2808522

http://www.w3.org/2001/XMLSchema#string